Business Wire

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Share

Abiomed (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock (AMICS) patients during the Society for Cardiovascular Angiography and Interventions (SCAI) 2022 Scientific Sessions, May 19 – 22, in Atlanta.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005230/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Impella RP with SmartAssist is the first single-access temporary percutaneous ventricular support device with dual-sensor technology. (Photo: Business Wire)

Below is a summary of Abiomed’s SCAI highlights:

Large Meta-Analysis Shows Association Between Pre-PCI Impella Support and Increased Survival

Researchers identified 13 studies in the PubMed and Cochrane databases, representing 6,810 AMICS patients. The patients were divided into two groups – those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840). The data showed significantly reduced short-term mortality rates in AMICS patients who received Impella support pre-PCI, compared to those who received Impella support during or post-PCI (37.2% vs 53.6%, p=0.002). Midterm mortality was also lower in AMICS patients who received Impella support pre-PCI compared to those who received it during or post-PCI (47.9% vs 73%, p=0.022).

This meta-analysis published online on May 6 in the International Journal of Cardiology. Lead author Mario Iannaccone, MD, an interventional cardiologist at San Giovanni Bosco Hospital, ASL Città di Torino, Turin, Italy, will present the study results at SCAI on Friday, May 20, starting at 12:00 pm EDT. Details of the presentation and the study abstract are available on the SCAI 2022 Scientific Sessions website.

“These results add to a plurality of evidence that the timing of Impella placement for AMICS may impact mortality rates, and that placing AMICS patients on Impella support prior to PCI can improve their survival in both the short and midterm,” said Dr. Iannaccone.

Impella RP with SmartAssist Full Market Launch

SCAI will mark the full market launch of Impella RP with SmartAssist, the only right heart pump equipped with dual-sensor technology to assist with pump management. Impella RP with SmartAssist pumps blood from the inferior vena cava to the pulmonary artery and enables biventricular support when the left side is supported with a left-side Impella. The FDA has granted its highest level of approval to Impella RP with SmartAssist to provide circulatory support for up to 14 days in certain patients.

Data from the SHOCK Trial and Registry has shown that 37% of AMICS patients exhibit right ventricular dysfunction, which leads to a three times increased risk of mortality. A FDA post-market approval study showed the use of Impella RP within 48 hours of cardiogenic shock onset leads to 73% survival, compared to 14% survival when implanted after 48 hours of cardiogenic shock when heart failure is present.

Heparin-free Impella Purge

SCAI also provides Abiomed an opportunity to highlight its latest FDA approval, which simplifies Impella management with the goal of improving patient outcomes. On April 19, the US Food and Drug Administration granted pre-market approval for the use of sodium bicarbonate purge solution as an alternative to heparin. This sodium bicarbonate option is for patients who are intolerant to heparin or for whom heparin is contraindicated due to heparin-induced thrombocytopenia or bleeding.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.

ABOUT IMPELLA HEART PUMPS

Impella 2.5® and Impella CP® are US FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.

Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are US FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

Impella RP® and the Impella RP® with SmartAssist® System are U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com

Investor:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis2.7.2022 15:08:00 CEST | Press release

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis. The retrospective longitudinal pharmaco-epidemiological real-world study included over 430,000 patients: more than 100,000 patients with allergic rhinitis with or without asthma treated with sublingual liquid immunotherapy and symptomatic drugs; compared to more than 330,000 patients with allergic rhinitis with or without asthma treated with symptomatic drugs only. The primary objective of the study was the evaluation of the impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. St

Boyd Acquires Sensata’s Thermal Test and Controls Business1.7.2022 17:29:00 CEST | Press release

Boyd, a world-leading innovator of technologies in engineered materials and thermal management, announced it acquired Sensata’s Thermal Test and Controls Business (NYSE:ST). This business specializes in the design and manufacturing of advanced thermal control systems, adapters, and sockets critical to the thermal test process for high-end logic and memory semiconductors. With a long history of serving leading global semiconductor companies, the addition complements Boyd’s existing thermal business, which includes air and liquid cooled thermal management technologies. Boyd designs and manufactures complex thermal solutions for high-performance semiconductors used in applications such as 5G, hyperscale data center, eMobility, and artificial intelligence. With this acquisition, Boyd expands its offering to current semiconductor customers by adding advanced controls and thermal test systems essential to the production of high-end memory and logic devices. “This acquisition is a natural fit

IFF Completed Divestiture of Microbial Control Business1.7.2022 15:45:00 CEST | Press release

IFF (NYSE:IFF) today announced that it has successfully completed the previously announced divestiture of its Microbial Control business unit to LANXESS. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet.Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn. © 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005790/en/Contact information Michael DeVeau Chief Investor Relations

Digi International Unveils Digi XBee LR Module for LoRaWAN Connectivity for IoT Deployments1.7.2022 15:00:00 CEST | Press release

Digi International®, (NASDAQ: DGII), a leading global provider of Internet of Things (IoT) connectivity products, solutions, and services, today unveiled the Digi XBee® LR, the first XBee-class pre-integrated and pre-certified wireless communication module for sensors and end-nodes using LoRaWAN. Coupled with the rich connectivity, device and gateway management capabilities of Digi X-ON™—its Low-Power Wide Area (LPWA) IoT data cloud platform—Digi provides a complete IoT solution with automated provisioning and deployment to help enterprises achieve significant ROI and faster market access. The Digi XBee LR module brings a new connectivity option to one of the most widely adopted wireless IoT module footprints, with more than 20 million devices deployed. This fully developed, tested, and certified module gives OEMs the freedom to create innovative public- or private-cloud solutions for organizations in agriculture, energy, logistics, manufacturing, utilities, and other sectors. These ap

Juniper Networks Announces Cloud Metro Innovation to Drive Sustainable Business Growth for Service Providers1.7.2022 14:35:00 CEST | Press release

Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced the innovation that will power its vision and strategy for Cloud Metro – a new category of solutions for service providers, optimized for metro transformation and sustainable business growth. Traditional “retro” metro networks are device-centric and are buckling under the extreme scale, agility and experience demands that widespread digital transformation and the advent of 5G services are bringing. Today’s announcement focuses on enabling sustainable business growth, with a series of high-performance networking systems, powered by AI-enabled, cloud-delivered automation, specifically designed to build next generation Cloud Metro infrastructure. These systems will deliver significantly-reduced natural resource consumption capabilities to help sustain the planet, improved tools and simplified working methods to help sustain over-pressured operations teams, along with embedded service assurance and secur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom